Impact of olopatadine hydrochloride(allelock(R)) against scratching behavior of atopic dermatitis patients at night.
- Conditions
- Atopic dermatitis
- Registration Number
- JPRN-UMIN000010519
- Lead Sponsor
- Mie University, Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Not provided
1)Those who may be pregnant or possible pregnant. 2)Those who have critical renal dysfunction and an impaired liver function. 3)The person under the specific or nonspecific de-sensitization treatment. 4)Those who took or injected a steroid, methotrexate, and cyclosporin in two weeks of the test . 5)Those who took the antihistamine within one week before the trial. 6)Those who have been engaged in business, such as operation of the car or machine. 7)The patient who is under the treatment of PUVA therapy using photo-senstive pills. 8)The patient with hypersensitivity or a drug-induced organ injury in the past with the use of Olopatadine, such as a Olopatadine hydrochloride (areroc(R)) and eye-drops Patanol (R). 9)Have lactose intolerance. 10)The person who is unsuitable for the entry judged by a doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measurement of the scratching ratio and depth of the sleep. The measurement will be performed on the day -2, -1 and 7 for atopic dermatitis patients. The measurement on day 7 day can be extended up to other 3 days, in case the subject is not available on day7. The VAS value of itch and the dermatitis score (EASI,ELQI) are measured for atopic dermatitis patient. Medication and the measurement on day 7 will not be performed for the healthy individuals.
- Secondary Outcome Measures
Name Time Method